Efficacy of Trigeminal Nerve Stimulation for ADHD
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles and Seattle, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 218 people enrolled
- Started
- 1 Sept 2022
- Ended
- 10 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Active eTNS
- Sham eTNS
- Record updated
- 14 May 2026
Who can take part
- Age
- 7 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- male and female children ages 7 to 12 years with DSM-5 ADHD, any current presentation, as determined by diagnostic interview, Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS), and clinical interview
- total score >= 24 on baseline ADHD-RS
- CGI-S score at baseline >= 4
- no current medication with CNS effects (Participants previously on psychostimulant medication will be required to be not optimally treated and off medication for one week or 5 half-lives for all other medications); stable use of supplements will be permitted
- parents able and willing to monitor proper use of the stimulation device and complete all required rating scales
- estimated Full Scale IQ >= 80 based on WASI subtests
- parent and participant able to complete rating scales and other measures in English
- able to cooperate during EEG
Who cannot take part
- impaired functioning to a degree that requires immediate initiation of ADHD medication in the opinion of the parents and/or investigator
- current diagnosis of autism spectrum disorder or major depression
- history of lifetime psychosis, mania, or seizure disorder
- history of seizure disorder or head injury with loss of consciousness
- baseline suicidality
Where in United States
- University of California, Los AngelesLos Angeles, United States
- Seattle Children's HospitalSeattle, United States
About the trial
What the trial wants to find out
This study is a large multisite randomized clinical trial to asses the efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal risk, non-invasive neuromodulation treatment, for ADHD in children ages 7-12 years old (N=180).
Read full original descriptionShow less
Study hypotheses address potential differences in ADHD symptoms over 4 weeks treatment with active vs. sham TNS in an expanded multi-site investigation; whether resting state fronto-parietal connectivity mediates TNS impact on ADHD symptoms; if changes in fronto-parietal activation, as measured by electroencephalography (EEG), predict TNS-related treatment outcomes; and whether a baseline cognitive profile similarly predicts response to TNS therapy.
The 2 groups in the trial
- Active eTNSTreatment being tested
Following screening and determination of eligibility , participants at baseline are randomized to receive 4 weeks nightly treatment with active eTNS. Positive responders will be invited to participate in a 12-month open-label continuation phase.
- Sham eTNSSham treatment, for comparison
Following screening and determination of eligibility, participants at baseline are randomize to receive 4 weeks nightly treatment with sham eTNS. At conclusion of the double-blind phase, participants randomized to sham will be provided an opportunity to receive an additional 4 weeks nightly treatment with active eTNS. Positive responders to active eTNS will be invited to participate in a 12-month open-label continuation phase.
Treatment: Active eTNS and Sham eTNS
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD
- Record updated
- 14 May 2026